22.05.2012 • News

DSM Invests in New R&D Facilities in the Netherlands

DSM is going to invest approximately €100 million in three new R&D facilities in Delft and Sittard-Geleen (both in the Netherlands) over the next two years.

The investment in Delft concerns a new laboratory for biotechnological research as well as a DSM contribution to the recently formed consortium for the Bioprocess Pilot Facility (BPF) for bio-research.

In Sittard-Geleen a new materials sciences research building will be realized on the Chemelot Campus.

The laboratories in Delft and Sittard-Geleen, where some 700 researchers will be working, are expected to open their doors in 2014. .

 

 

 

 

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read